Long-term treatment of severe SAPHO syndrome with adalimumab: Case report and a review of the literature

American Journal of Clinical Dermatology

Volumn 13, Issue 1, 2012, Pages 55-59

  Garcovich, Simone ^a   Amelia, Rosanna ^b   Magarelli, Nicola ^b   Valenza, Venanzio ^b   Amerio, Pierluigi ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Acne; Adalimumab; Etanercept; Hyperostosis; Infliximab; Isotretinoin; Osteitis; Pustulosis; Synovitis

Indexed keywords

ADALIMUMAB; ALENDRONIC ACID; C REACTIVE PROTEIN; HYDROCORTISONE; ISOTRETINOIN; METHOTREXATE; MONOCLONAL ANTIBODY; NIMESULIDE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACNE; ACNE CONGLOBATA; ADRENAL INSUFFICIENCY; ADULT; ANKYLOSIS; ARTICLE; BODY MASS; BONE EROSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISABILITY; DISEASE COURSE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LOW BACK PAIN; LOW DRUG DOSE; MALE; OSTEITIS; PRIORITY JOURNAL; SACROILIAC JOINT; SAPHO SYNDROME; SCINTIGRAPHY; SKIN DEFECT; THORAX PAIN; VISUAL ANALOG SCALE;

ACQUIRED HYPEROSTOSIS SYNDROME; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; HUMANS; ISOTRETINOIN; MALE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84055193724     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11593250-000000000-00000     Document Type: Article

References (27)

1. Chamot AM, Benhamou CL, Kahn MF, et al. Acne-pustulosis- hyperostosisosteitis syndrome: results of a national survey. 85 cases [in French]. Rev Rhum Mal Osteoartic 1987; 54: 187-96 (Pubitemid 17033750)
2. Levin J, Werth VP. Skin disorders with arthritis. Best Pract Res Clin Rheumatol 2006; 20 (4): 809-26 (Pubitemid 44350118)
3. Hughes RA. Arthritis precipitated by isotretinoin treatment for acne vulgaris. J Rheumatol 1993; 20: 1241-2 (Pubitemid 23278187)
4. Pedraz T, Martínez A, Pascual E. Acute hip monoarthritis in a patient treated with isotretinoin. J Clin Rheumato 2006; 12: 105-6 (Pubitemid 44309611)
5. Rohekar G, Inman RD. Conundrums in nosology: synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome and spondylarthritis. Arthritis Rheum 2006; 55: 665-9 (Pubitemid 44289889)
6. Olivieri I, Padula A, Ciancio G, et al. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 2002; 6: 375-6 (Pubitemid 34257756)
7. Wagner AD, Andresen J, Jendro MC, et al. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002; 46: 1965-8 (Pubitemid 34774530)
8. Deutschmann A, Mache CJ, Bodo K, et al. Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-alpha blockage. Pediatrics 2005; 116: 1231-3 (Pubitemid 46056433)
9. Moll C, Herná ndez MV, Cañete JD, et al. Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. Semin Arthritis Rheum 2008; 37: 299-306 (Pubitemid 351389483)
10. Sabugo F, Liberman C, Niedmann JP, et al. Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism. Clin Rheumatol 2008; 27: 533-5 (Pubitemid 351404307)
11. Wagner AD, Andresen J, Jendro MC, et al. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002; 46: 1965-8 (Pubitemid 34774530)
12. Eleftheriou D, Gerschman T, Sebire N, et al. Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. Rheumatology (Oxford) 2010; 49: 1505-12
13. Widmer M, Weishaupt D, Brühlmann P, et al. Infliximab in the treatment of SAPHO syndrome: clinical experience and MRI response [abstract]. Ann Rheum Dis 2003; 62: 250-1A
14. Asmussen KH. Successful treatment of SAPHO syndrome with infliximab: a case report [abstract]. Arthritis Rheum 2003; 48 Suppl.: S621A
15. Kyriazis NC, Tachoula AV, Sfontouris CI. Successful treatment of refractory SAPHO syndrome with infliximab [abstract]. Ann Rheum Dis 2004; 63: 388-9A
16. Fruehauf J, Cierny-Modrè B, Caelen Lel-S, et al. Response to infliximab in SAPHO syndrome. BMJ Case Rep. Epub 2009 May 20
17. Vilar-Alejo J, Dehesa L, de la Rosa-del Rey P, et al. SAPHO syndrome with unusual cutaneous manifestations treated successfully with etanercept. Acta Derm Venereol 2010; 90: 531-2
18. Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P, et al. Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology (Oxford) 2008; 47: 1160-7 (Pubitemid 352038220)
19. Wolber C, David-Jelinek K, Udvardi A, et al. Successful therapy of sacroiliitis in SAPHO syndrome by etanercept [in German]. Wien Med Wochenschr 2011; 161: 204-8
20. Castellví I, Bonet M, Narvá ez JA, et al. Successful treatment of SAPHO syndrome with adalimumab: a case report. Clin Rheumatol 2010; 29: 1205-7
21. Ben Abdelghani K, Dran DG, Gottenberg JE, et al. Tumor necrosis factoralpha blockers in SAPHO syndrome. J Rheumatol 2010; 37: 1699-704
22. Arias-Santiago S, Sanchez-Cano D, Callejas-Rubio JL, et al. Adalimumab treatment for SAPHO syndrome. Acta Derm Venereol 2010; 90: 301-2
23. Massara A, Cavazzini PL, Trotta F. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology (Oxford) 2006; 45: 730-3 (Pubitemid 43985342)
24. Iqbal M, Kolodney MS. Acne fulminans with synovitis-acne- pustulosishyperostosis- osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol 2005; 52: 118-20
25. Bassi E, Poli F, Charachon A, et al. Infliximab-induced acne: report of two cases. Br J Dermatol 2007; 156: 402-3 (Pubitemid 46095989)
26. Galadari H, Bishop AG, Venna SS, et al. Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome treated with a combination of isotretinoin and pamidronate. J Am Acad Dermatol 2009; 61: 123-5
27. DawsonHD, Collins G, Pyle R, et al. The retinoic acid receptor-alpha mediates human T-cell activation and Th2 cytokine and chemokine production. BMC Immunol 2008; 9: 16